The upcoming earnings report for Gilead Sciences, Inc. (GILD) is scheduled for Wednesday, May 6th, with a consensus estimated EPS of 1.89.
GILD is currently priced at $129.41, showing a price increase of $1.66 (1.3%) from the previous close at $127.75. The trading volume is $1.48 million, which is 22.48% higher than the average.
GILD's latest quarterly earnings report, released on Wednesday, April 22nd, revealed an EPS of 1.86, slightly below the consensus estimate. Further revenue and profit margin figures are pending.
GILD offers a forward dividend yield of 2.53%, with a dividend per share MRQ of 82 cents and a total TTM dividend per share of $3.19.
GILD's cash flow highlights a free cash flow of $3.12 billion. Noteworthy transactions include acquisitions netting -$609 million and common stock repurchases amounting to -$230 million.
The income statement showcases GILD's revenue at $7.92 billion, gross profit at $6.88 billion, and a net income of $2.18 billion, resulting in an EPS of $1.76.
Key ratios for GILD include a net profit margin of 27.55%, return on equity of 9.65%, and a price to earnings ratio of 17.46, indicating the company's financial performance.
GILD's balance sheet reveals total assets of $59 billion, total liabilities of $36.41 billion, and a net debt position of $17 billion, reflecting the company's financial standing.
This comprehensive overview provides insights into GILD's current financial status and performance metrics ahead of its upcoming earnings report.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.